| Answer | Binimetinib | LA30251-5 |
| Answer | Imatinib | LA30253-1 |
| Answer | Sunitinib | LA30250-7 |
| Answer | Trametinib | LA30252-3 |
| Answer | Midostaurin | LA30247-3 |
| Answer | Sorafenib | LA30248-1 |
| Answer | Ponatinib | LA30249-9 |
| answers-for | Treatment to which interaction between genetic variants confers synergy [Identifier] in Blood or Tissue Nominal | 93343-2 |
| answers-for | Treatment to which genetic variant confers resistance [Identifier] in Blood or Tissue Nominal | 93344-0 |
| answers-for | Available treatment related to genetic variant and not to patient diagnosis [Identifier] in Blood or Tissue Nominal | 93347-3 |
| answers-for | Available treatment related to genetic variant and to patient diagnosis [Identifier] in Blood or Tissue Nominal | 93348-1 |
| answers-for | Treatment to which interaction between genetic variants confers resistance [Identifier] in Blood or Tissue Nominal | 93349-9 |
| LONG_COMMON_NAME | en-US | Cancer therapies |
LOINC Version: 2.77
FHIR